Biotechnology in the capital region of Europe

Abstract

It has never been as challenging in biotechnology as today. Convergence is the key word, forcing alliances between pharmaceuticals and biology, and new economic opportunities arise from the growing interface between biotechnology and nanotechnology, nanobio. The challenges to bring such disruptive technologies to the market are unprecedented, ranging from truly multidisciplinary research to matching totally different business models among the various industries. In Flanders, Belgium, the message has been understood already 20 years ago.